# Novo Nordisk vs Pfizer: valuation, size and margins compared

URL: https://funkfolio.com/compare/nvo-vs-pfe

> Novo Nordisk ($179.4B, P/E 10.5) and Pfizer ($162.3B, P/E 41.3) compared: size, valuation, margins, debt, cash and price change.

---

## Novo Nordisk vs Pfizer

Novo Nordisk (NVO), health care, and Pfizer (PFE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Novo Nordisk is worth $179.4B on the stock market and Pfizer $162.3B: Novo Nordisk is valued at 11% more. Novo Nordisk trades at 10.5 times earnings and Pfizer at 41.3. Over the past year Novo Nordisk's share price has moved -12.5% and Pfizer's +13.4%.

### Key facts

- **Novo Nordisk market value:** $179.4B
- **Pfizer market value:** $162.3B
- **Novo Nordisk P/E:** 10.5
- **Pfizer P/E:** 41.3
- **Novo Nordisk revenue:** $45.9B FY to 2025-12-31
- **Pfizer revenue:** $62.6B FY to 2025-12-31
- **Superinvestors holding both:** 2

Market values as of 18 Nov 2026, 04:50 UTC.

Novo Nordisk vs Pfizer: every measure side by side

| Measure | Novo Nordisk | Pfizer |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | Denmark | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $179.4B higher | $162.3B lower |
| Revenue | $45.9B lower | $62.6B higher |
| Earnings | $15.2B higher | $7.8B lower |
| Employees | 68,794 lower | 75,000 higher |
| Total assets | $80.6B lower | $208.2B higher |
| Valuation |  |  |
| P/E | 10.5 lower | 41.3 higher |
| P/S | 3.9 higher | 2.6 lower |
| P/B | — | 1.8 |
| Dividend yield | — | 7.45% |
| Profitability |  |  |
| Operating margin | 41.3% | — |
| Balance sheet |  |  |
| Net assets | $28.8B lower | $86.5B higher |
| Total liabilities | $51.8B lower | $121.4B higher |
| Total debt | $19.4B lower | $64.8B higher |
| Cash on hand | $3.9B higher | $1.1B lower |
| Price change |  |  |
| Today | -2.16% lower | -1.35% higher |
| 1 year | -12.5% lower | +13.4% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Novo Nordisk 84.0, Pfizer 113.5.

- Novo Nordisk (NVO)
- Pfizer (PFE)

Novo Nordisk and Pfizer share prices over one year, rebased to 100: Novo Nordisk ends at 84.0, Pfizer at 113.5.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | NVO | PFE |
| --- | --- | --- |
| Nov 28, 2025 | 101.8 | 102.6 |
| Dec 31, 2025 | 105.0 | 99.3 |
| Jan 30, 2026 | 122.6 | 105.4 |
| Feb 27, 2026 | 77.3 | 110.2 |
| Mar 31, 2026 | 75.8 | 112.0 |
| Apr 30, 2026 | 87.1 | 106.5 |
| May 29, 2026 | 94.1 | 104.4 |
| Jun 30, 2026 | 98.9 | 96.0 |
| Jul 31, 2026 | 97.2 | 99.7 |
| Aug 31, 2026 | 93.5 | 113.5 |
| Sep 30, 2026 | 78.2 | 113.7 |
| Oct 30, 2026 | 82.5 | 121.7 |
| Nov 17, 2026 | 84.0 | 113.5 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (2)

- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2% / 1.5%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.1% / 0.9%

#### Novo Nordisk only (6)

- [Tom Gayner](https://funkfolio.com/gurus/tom-gayner) 0.8%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) 0.7%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.6%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 0.4%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.2%

#### Pfizer only (9)

- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 1.9%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 1.6%
- [Prem Watsa](https://funkfolio.com/gurus/prem-watsa) 1.5%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 1.0%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) 0.5%
- [Bruce Berkowitz](https://funkfolio.com/gurus/bruce-berkowitz) 0.4%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Novo Nordisk / Pfizer). [Who owns NVO](https://funkfolio.com/stock/NVO/superinvestors) · [Who owns PFE](https://funkfolio.com/stock/PFE/superinvestors)

### More on Novo Nordisk

- [Novo Nordisk (NVO) stock page](https://funkfolio.com/stock/NVO)
- [Novo Nordisk market cap](https://funkfolio.com/stock/NVO/market-cap)
- [Novo Nordisk revenue](https://funkfolio.com/stock/NVO/revenue)
- [Novo Nordisk P/E ratio](https://funkfolio.com/stock/NVO/pe-ratio)
- [Novo Nordisk operating margin](https://funkfolio.com/stock/NVO/operating-margin)
- [Novo Nordisk total debt](https://funkfolio.com/stock/NVO/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Pfizer

- [Pfizer (PFE) stock page](https://funkfolio.com/stock/PFE)
- [Pfizer market cap](https://funkfolio.com/stock/PFE/market-cap)
- [Pfizer revenue](https://funkfolio.com/stock/PFE/revenue)
- [Pfizer P/E ratio](https://funkfolio.com/stock/PFE/pe-ratio)
- [Pfizer operating margin](https://funkfolio.com/stock/PFE/operating-margin)
- [Pfizer total debt](https://funkfolio.com/stock/PFE/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Novo Nordisk against its closest peers

- [Novo Nordisk vs Abbott Laboratories](https://funkfolio.com/compare/abt-vs-nvo)
- [Novo Nordisk vs Danaher](https://funkfolio.com/compare/dhr-vs-nvo)
- [Novo Nordisk vs Intuitive Surgical](https://funkfolio.com/compare/isrg-vs-nvo)

#### Pfizer against its closest peers

- [Pfizer vs Danaher](https://funkfolio.com/compare/dhr-vs-pfe)
- [Pfizer vs Intuitive Surgical](https://funkfolio.com/compare/isrg-vs-pfe)
- [Pfizer vs Abbott Laboratories](https://funkfolio.com/compare/abt-vs-pfe)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Novo Nordisk or Pfizer?**

By market value, Novo Nordisk is the larger: $179.4B against $162.3B for Pfizer. By revenue in its latest fiscal year, Pfizer is the larger: $62.6B against $45.9B for Novo Nordisk.

**Which has the higher P/E ratio?**

Pfizer: 41.3, against 10.5 for Novo Nordisk. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has more debt?**

Pfizer: $64.8B, against $19.4B for Novo Nordisk. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Novo Nordisk and Pfizer?**

In their latest 13F filings, Charles Brandes (founder) and Ken Fisher hold both.

### Cite this page

Funkfolio, “Novo Nordisk vs Pfizer”, data as of 18 November 2026. https://funkfolio.com/compare/nvo-vs-pfe

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
